

Afatinib LUX - Lung 8

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Improved QoL

Serious and disabling adverse effects



Other adjustments



Afatinib LUX - Lung 8

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: As monotherapy for the treatment of locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based ChT
Experimental Arm: Afatinib
Control Arm: Erlotinib



